Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

BACKGROUND: Olaparib (AZD2281), a PARP-1/2 inhibitor, has been extensively investigated in clinical trials. However, limited clinical data are available about its long-term safety and anti-tumour activity. METHODS: Patients had first participated in a phase I study of olaparib combined with carbopla...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: van der Noll, Ruud, Marchetti, Serena, Steeghs, Neeltje, Beijnen, Jos H, Mergui-Roelvink, Marja W J, Harms, Emmy, Rehorst, Harriet, Sonke, Gabe S, Schellens, Jan H M
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2015
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522644/
https://ncbi.nlm.nih.gov/pubmed/26180927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.256
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares